Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.964
-0.016 (-1.66%)
At close: Dec 20, 2024, 4:00 PM
0.990
+0.026 (2.74%)
After-hours: Dec 20, 2024, 7:36 PM EST
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
121.23M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
American Well | 254.04M |
Enanta Pharmaceuticals | 67.64M |
Sensus Healthcare | 41.31M |
Zomedica | 26.73M |
Elutia | 24.78M |
InflaRx | 187.93K |
Applied Therapeutics | -212.00K |
ATOS News
- 9 days ago - Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 10 days ago - Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - GlobeNewsWire
- 11 days ago - Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 12 days ago - Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research - GlobeNewsWire
- 4 weeks ago - Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research - GlobeNewsWire
- 4 weeks ago - Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 5 weeks ago - Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development - GlobeNewsWire